BEAM is trading at $36.87 (4.39% up) after reporting promising Phase 1/2 clinical data for its BEAM-302 gene-editing program.
- The study demonstrated sustained alpha-1 antitrypsin levels for up to 12 months, with the company planning to initiate a global trial in the second half of 2026.
- The upward move is also supported by broader risk-on interest in biotech and growth stocks as sentiment around the name turns increasingly constructive.